A Pilot Study of Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (GRIP-IT PILOT)
A Pilot Study of Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (GRIP-IT PILOT) is a PHASE1 clinical asset sponsored by Duke University in Hyperglycemia Drug Induced. SEO and diligence focus: REMD-477, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Hyperglycemia Drug Induced
Modality: protein therapy
Target: REMD-477
Sponsor: Duke University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: REMD-477
View original source fields
Condition raw: Hyperglycemia Drug Induced
Condition normalized: Hyperglycemia Drug Induced
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: REMD-477
Target normalized: REMD-477